Indicated for the treatment of chronic hepatitis B virus infection in adults and adolescents (aged 12 years and older with body weight at least 35 kg): 🦠 Compensated Liver Disease: Effective for HBeAg-positive and HBeAg-negative patients. 🔄 Switching Therapy: Ideal for patients transitioning from Tenofovir Disoproxil Fumarate (TDF) due to bone or renal concerns.

Dosage and administration

Packaging: Bottle of 30 tablets (1-month supply). ⚠️ DOSAGE PROTOCOL: 💊 Standard Dose: One tablet (25 mg) taken once daily. 🍽️ Administration: Must be taken WITH FOOD. Food increases the absorption and efficacy of the drug. ⏰ Consistency: Do not miss doses. Adherence is critical to prevent drug resistance. 📅 Duration: Often indefinite (long-term). Do not stop taking without consulting a hepatologist, as severe acute exacerbation of Hepatitis B may occur.

Severe hypersensitivity to Tenofovir Alafenamide. Breastfeeding (safety not established). Children under 12 years of age. Patients with end-stage renal disease (CrCl < 15 mL/min) who are not receiving chronic hemodialysis.

Tafnext is generally well-tolerated: 🤕 Common: Headache, fatigue. 🤢 Gastrointestinal: Nausea, abdominal pain (usually mild). 📉 Advantage: Significantly lower risk of osteoporosis and renal tubulopathy compared to older Tenofovir (TDF) formulations.

Tafnext — Tenofovir Alafenamide 25 mg, 30 pcs, Aprazer

100% original product

Active ingredient

Tenofovir Alafenamide

Manufacturer

Aprazer

Dosage 25 mg

Dosage form Tablets

Tablets per pack 30

Tafnext (Tenofovir Alafenamide) Tablets

Name: Tafnext
Brand: Aprazer
SKU: PROD-125
Price: 1011 UAH
Availability: InStock

1011₴ ~~1275₴~~ -21%

Tafnext (Tenofovir Alafenamide 25 mg) is a next-generation antiviral medication, a generic version of Vemlidy, produced by Aprazer.

It is a Nucleotide Reverse Transcriptase Inhibitor (NRTI) designed specifically for the treatment of Chronic Hepatitis B (HBV). TAF is an advanced prodrug of Tenofovir that delivers the active substance directly to hepatocytes (liver cells) more efficiently than the older formulation (TDF).

Key Benefit ("Kidney & Bone Safety"):

Because it works at a much lower dose (25 mg vs 300 mg), Tafnext has significantly less toxicity to the kidneys and bones. This makes it the preferred choice for long-term maintenance therapy in aging populations or those with renal risks.

✅ Goal: Potent viral suppression with an improved safety profile.

Indicated for the treatment of chronic hepatitis B virus infection in adults and adolescents (aged 12 years and older with body weight at least 35 kg):

🦠 Compensated Liver Disease: Effective for HBeAg-positive and HBeAg-negative patients.
🔄 Switching Therapy: Ideal for patients transitioning from Tenofovir Disoproxil Fumarate (TDF) due to bone or renal concerns.

Packaging: Bottle of 30 tablets (1-month supply).

⚠️ DOSAGE PROTOCOL:

💊 Standard Dose: One tablet (25 mg) taken once daily.
🍽️ Administration: Must be taken WITH FOOD. Food increases the absorption and efficacy of the drug.
⏰ Consistency: Do not miss doses. Adherence is critical to prevent drug resistance.
📅 Duration: Often indefinite (long-term). Do not stop taking without consulting a hepatologist, as severe acute exacerbation of Hepatitis B may occur.

Severe hypersensitivity to Tenofovir Alafenamide.
Breastfeeding (safety not established).
Children under 12 years of age.
Patients with end-stage renal disease (CrCl < 15 mL/min) who are not receiving chronic hemodialysis.

Tafnext is generally well-tolerated:

🤕 Common: Headache, fatigue.
🤢 Gastrointestinal: Nausea, abdominal pain (usually mild).
📉 Advantage: Significantly lower risk of osteoporosis and renal tubulopathy compared to older Tenofovir (TDF) formulations.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 08.03.2026